Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.pSivida has announced positive results from the Phase IIa clinical trial of BrachySil for the treatment of advanced, inoperable pancreatic cancer.
Subscribe to our email newsletter
The trial, designed as a safety study, successfully showed that BrachySil, in combination with standard chemotherapy (gemcitabine), was well tolerated with no clinically significant adverse events related to BrachySil. Data showed disease control in 82% of patients and an overall median survival of 309 days.
BrachySil was found to be easily deliverable by endoscopic ultrasound. BrachySil is a novel oncology product which comprises a combination of BioSilicon, a proprietary porous silicon, and the isotope 32Phosphorus, a proven anti-cancer therapeutic.